加齢性黄斑変性症治療薬市場:パイプラインレビュー(2019年下半期)

◆英語タイトル:Age Related Macular Degeneration - Pipeline Review, H2 2019
◆商品コード:GDATA20MY0648
◆発行会社(リサーチ会社):Global Markets Direct
◆発行日:2019年12月27日
◆ページ数:753
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆調査対象地域:グローバル
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD2,500 ⇒換算¥262,500見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD5,000 ⇒換算¥525,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD7,500 ⇒換算¥787,500見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobal Markets Direct社の日本における正規販売代理店です。同社発行の医療分野調査レポートに関するお問い合わせは弊社までお願い致します。
Global Markets Direct社の概要はこちらでご確認いただけます。
※上記「見積依頼/購入/質問フォーム」をクリックすると弊社運営のレポート販売サイトに移動します。

【レポートの概要】

Age Related Macular Degeneration – Pipeline Review, H2 2019
Summary

Global Markets Direct’s latest Pharmaceutical and Healthcare disease pipeline guide Age Related Macular Degeneration – Pipeline Review, H2 2019, provides an overview of the Age Related Macular Degeneration (Ophthalmology) pipeline landscape.

Age related macular degeneration is the most common reason for vision loss in people aged above 50. It results in depreciation of the macula that may lead to distorted or blurry central vision. The predisposing factors involved are age, smoking, sunlight, heredity etc. Symptoms include development of blind spot and hazy vision. The condition may be treated by photodynamic therapy, radiation therapy and medication such as anti-angiogenic drugs.

Report Highlights

Global Markets Direct’s Pharmaceutical and Healthcare latest pipeline guide Age Related Macular Degeneration – Pipeline Review, H2 2019, provides comprehensive information on the therapeutics under development for Age Related Macular Degeneration (Ophthalmology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Age Related Macular Degeneration (Ophthalmology) pipeline guide also reviews of key players involved in therapeutic development for Age Related Macular Degeneration and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 2, 15, 32, 32, 3, 154, 31 and 3 respectively. Similarly, the Universities portfolio in Phase I, Preclinical and Discovery stages comprises 1, 16 and 1 molecules, respectively.

Age Related Macular Degeneration (Ophthalmology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Age Related Macular Degeneration (Ophthalmology).
- The pipeline guide reviews pipeline therapeutics for Age Related Macular Degeneration (Ophthalmology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Age Related Macular Degeneration (Ophthalmology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Age Related Macular Degeneration (Ophthalmology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Age Related Macular Degeneration (Ophthalmology)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Age Related Macular Degeneration (Ophthalmology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Age Related Macular Degeneration (Ophthalmology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

【レポートの目次】

Table of Contents
Introduction
Age Related Macular Degeneration – Overview
Age Related Macular Degeneration – Therapeutics Development
Age Related Macular Degeneration – Therapeutics Assessment
Age Related Macular Degeneration – Companies Involved in Therapeutics Development
Age Related Macular Degeneration – Drug Profiles
Age Related Macular Degeneration – Dormant Projects
Age Related Macular Degeneration – Discontinued Products
Age Related Macular Degeneration – Product Development Milestones
Appendix

List of Tables
Number of Products under Development for Age Related Macular Degeneration, H2 2019
Number of Products under Development by Companies, H2 2019
Number of Products under Development by Universities/Institutes, H2 2019
Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019 (Contd..1), H2 2019
Products under Development by Companies, H2 2019 (Contd..2), H2 2019
Products under Development by Companies, H2 2019 (Contd..3), H2 2019
Products under Development by Companies, H2 2019 (Contd..4), H2 2019
Products under Development by Companies, H2 2019 (Contd..5), H2 2019
Products under Development by Companies, H2 2019 (Contd..6), H2 2019
Products under Development by Companies, H2 2019 (Contd..7), H2 2019
Products under Development by Companies, H2 2019 (Contd..8), H2 2019
Products under Development by Companies, H2 2019 (Contd..9), H2 2019
Products under Development by Companies, H2 2019 (Contd..10), H2 2019
Products under Development by Companies, H2 2019 (Contd..11), H2 2019
Products under Development by Companies, H2 2019 (Contd..12), H2 2019
Products under Development by Companies, H2 2019 (Contd..13), H2 2019
Products under Development by Companies, H2 2019 (Contd..14), H2 2019
Products under Development by Companies, H2 2019 (Contd..15), H2 2019
Products under Development by Universities/Institutes, H2 2019
Number of Products by Stage and Target, H2 2019
Number of Products by Stage and Target, H2 2019 (Contd..1), H2 2019
Number of Products by Stage and Target, H2 2019 (Contd..2), H2 2019
Number of Products by Stage and Target, H2 2019 (Contd..3), H2 2019
Number of Products by Stage and Target, H2 2019 (Contd..4), H2 2019
Number of Products by Stage and Mechanism of Action, H2 2019
Number of Products by Stage and Mechanism of Action, H2 2019 (Contd..1), H2 2019
Number of Products by Stage and Mechanism of Action, H2 2019 (Contd..2), H2 2019
Number of Products by Stage and Mechanism of Action, H2 2019 (Contd..3), H2 2019
Number of Products by Stage and Mechanism of Action, H2 2019 (Contd..4), H2 2019
Number of Products by Stage and Route of Administration, H2 2019
Number of Products by Stage and Molecule Type, H2 2019
Age Related Macular Degeneration - Pipeline by 3SBio Inc, H2 2019
Age Related Macular Degeneration - Pipeline by 4D Molecular Therapeutics Inc, H2 2019
Age Related Macular Degeneration - Pipeline by Abpro Corp, H2 2019
Age Related Macular Degeneration - Pipeline by Abzyme Therapeutics LLC, H2 2019
Age Related Macular Degeneration - Pipeline by Achillion Pharmaceuticals Inc, H2 2019
Age Related Macular Degeneration - Pipeline by Acucela Inc, H2 2019
Age Related Macular Degeneration - Pipeline by AdAlta Ltd, H2 2019
Age Related Macular Degeneration - Pipeline by Adverum Biotechnologies Inc, H2 2019
Age Related Macular Degeneration - Pipeline by Aerie Pharmaceuticals Inc, H2 2019

【掲載企業】

3SBio Inc
4D Molecular Therapeutics Inc
Abpro Corp
Abzyme Therapeutics LLC
Achillion Pharmaceuticals Inc
Acucela Inc
AdAlta Ltd
Adverum Biotechnologies Inc
Aerie Pharmaceuticals Inc
Aerpio Pharmaceuticals Inc
Aevitas Therapeutics Inc
Affilogic SAS
Aibios Co Ltd
Aldeyra Therapeutics Inc
Alimera Sciences Inc
Alkahest Inc
Alkeus Pharmaceuticals Inc
Allegro Ophthalmics LLC
Allergan Plc
Allgenesis Biotherapeutics Inc
Alpine Biotherapeutics Corp
Alteogen Inc
Alzheon Inc
Amarantus Bioscience Holdings Inc
Amarna Therapeutics BV
Amyndas Pharmaceuticals LLC
AngioGenex Inc
Anida Pharma Inc
Annexon Inc
Apellis Pharmaceuticals Inc
Apexian Pharmaceuticals Inc
Apexigen Inc
Applied Genetic Technologies Corp
AptaBio Therapeutics Inc
Aptamer Sciences Inc
Ascentage Pharma Group International
Asclepiumm Taiwan Co Ltd
AsclepiX Therapeutics Inc
Astellas Pharma Inc
AVEO Oncology Inc
Avixgen Inc
Beijing Eastern Biotech Co Ltd
BellBrook Labs LLC
Benitec Biopharma Ltd
Beta Therapeutics Pty Ltd
Bio-Thera Solutions Ltd
BIOCND Inc
Biocure Technology Inc
Bioeq GmbH
Biogen Inc
Biokine Therapeutics Ltd
Biomics Biotechnologies Co Ltd
Biophytis SA
Boehringer Ingelheim International GmbH
Bridge Biotherapeutics Inc
Cadila Healthcare Ltd
Catalyst Biosciences Inc
Cell Care Therapeutics Inc
Cell Cure Neurosciences Ltd
Cell Medica Ltd
Celon Pharma SA
Charlesson LLC
Chengdu Kanghong Pharmaceuticals Group Co Ltd
Chong Kun Dang Pharmaceutical Corp
CHS Pharma Inc
Cinnagen Co
Cipla BioTec Pvt Ltd
CJ HealthCare Corp
Clayton Biotechnologies Inc
Clearside BioMedical Inc
Clover Biopharmaceuticals
Coherus BioSciences Inc
CureLab Oncology Inc
Daiichi Sankyo Co Ltd
DNX Biopharmaceuticals Inc
Dobecure SL
Dong-A Socio Holdings Co Ltd
EirGenix Inc
Elasmogen Ltd
Elsalys Biotech SA
Envisia Therapeutics Inc
Enzene Biosciences Ltd
Epygen Biotech Pvt Ltd
Everglades Biopharma LLC
Exonate Ltd
Eye Co Pty Ltd
Eyedesis Biosciences LLC
EyeGate Pharmaceuticals Inc
EyePoint Pharmaceuticals Inc
Eyestem Research Pvt Ltd
Eyevensys SAS
F. Hoffmann-La Roche Ltd
Feramda Ltd
FirstString Research Inc
Formycon AG
Galimedix Therapeutics Ltd
Gemini Therapeutics Inc
Gene Signal International SA
Gene Techno Science Co Ltd
Genentech Inc
Generium
GenSight Biologics SA
Graybug Vision Inc
Gyroscope Therapeutics Ltd
Hanlim Pharm Co Ltd
Hemera Biosciences Inc
Hengenix Biotech Inc
Huabo Biopharm Co Ltd
Huons Global Co Ltd
Ichor Therapeutics Inc
Iconic Therapeutics Inc
Ildong Pharmaceutical Co Ltd
Immupharma Plc
Inflammasome Therapeutics Inc
Innovent Biologics Inc
Ionis Pharmaceuticals Inc
Isarna Therapeutics GmbH
iTherapeutics Corp
iVeena LLC
IVERIC bio Inc
Jeil Pharmaceutical Co Ltd
Johnson & Johnson
Kala Pharmaceuticals Inc
Kalos Therapeutics Inc
Katairo GmbH
Kodiak Sciences Inc
Kyowa Kirin Co Ltd
Lead Discovery Center GmbH
Lin Bioscience Inc
Lupin Ltd
Luye Pharma Group Ltd
Mabion SA
MacuCLEAR Inc
MeiraGTx Holdings Plc
Mitotech SA
Mitsubishi Tanabe Pharma Corp
Mor Research Applications Ltd
Mperia Therapeutics Inc
NanoScope Technologies LLC
Nanoscope Therapeutics Inc
Neovacs SA
NeuBase Therapeutics Inc
NeuExcell Therapeutics Inc
NGM Biopharmaceuticals Inc
Novartis AG
NovelMed Therapeutics Inc
Novelty Nobility Inc
OccuRx Pty Ltd
Ocugen Inc
Ocular Therapeutix Inc
OcuNexus Therapeutics Inc
ODIN Biotech Partners LLC
OliX Pharmaceuticals Inc
Omeros Corp
ONL Therapeutics Inc
Opthea Ltd
Outlook Therapeutics Inc
Oxford BioMedica Plc
Oxstem Ltd
Oxurion NV
PanOptica Inc
Paras Biopharmaceuticals Finland Oy
Pfizer Inc
Phanes Therapeutics Inc
PharmAbcine Inc
Phio Pharmaceuticals Corp
Phision Therapeutics
PlantForm Corp
Pleryon Therapeutics Ltd
Polus Inc
Profarma
Promedior Inc
Qilu Pharmaceutical Co Ltd
Reflexion Pharmaceuticals Inc
Regen BioPharma Inc
Regeneron Pharmaceuticals Inc
RegenxBio Inc
Reliance Life Sciences Pvt Ltd
RemeGen Ltd
Retrotope Inc
RheinCell Therapeutics GmbH
Ribomic Inc
RiniSight Inc
Samsung Bioepis Co Ltd
SanBio Inc
SciFluor Life Sciences LLC
Semathera Inc
Senju Pharmaceutical Co Ltd
Shanghai Junshi Bioscience Co Ltd
Splash Pharmaceuticals Inc
Stealth BioTherapeutics Corp
Sumitomo Dainippon Pharma Co Ltd
Sustained Nano Systems LLC
Suzhou Kintor Pharmaceutical Inc
Suzhou Stainwei Biotech Inc
Sylentis SAU
Taejoon Pharm Co Ltd
Tarsius Pharma Ltd
TechnoPhage SA
TOT Biopharm Co Ltd
TRACON Pharmaceuticals Inc
Translatum Medicus Inc
TreeFrog Therapeutics SAS
Visgenx Inc
Wellstat Ophthalmics Corp
Xbrane Biopharma AB
Xcovery Holding Company LLC
YD Life Science Co
Zhejiang Doer Biologics Corp


【免責事項】
https://www.marketreport.jp/reports-disclaimer

★医療情報レポート[加齢性黄斑変性症治療薬市場:パイプラインレビュー(2019年下半期)]についてメールでお問い合わせはこちら



◆H&Iグローバルリサーチ株式会社のお客様(例)◆